An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and Ethyl heptanoate (cas 106-30-9) as an additive: In-vitro, ex-vivo, and in-vivo release evaluation

Add time:08/20/2019    Source:sciencedirect.com

An in-situ forming implant formulation of naltrexone (NTX) was achieved based on a minimum initial burst release of NTX in the in-vitro release medium using a Box-Behnken design. Variables such as percent of copolymer by weight, copolymer composition (PLGA 756s: PLGA 504H), and percent Ethyl heptanoate (cas 106-30-9) by weight as an additive in formulation were investigated. The in-vitro, ex-vivo, and in-vivo release of the optimized formulation was investigated. The rabbit-blood concentrations of the optimized formulation and Vivitrol® were compared to ensure their equivalency. The initial burst release of the optimized formulation in the in-vitro release over the first 24 h, 6.18 ± 0.91%, was significantly (p < 0.05) lower than that of the formulation containing 100% of PLGA 504H (17.45 ± 1.07%) and 100% of PLGA 756s (11.82 ± 1.03%). The Cmax of NTX (21.06 ± 2.9 ng/mL) from the optimized formulation was close to that of Vivitrol® (21.11 ± 2.89 ng/mL). Also, the absolute bioavailability (F) and the range of serum concentration of NTX (C) of the ISFI formulation (F = 18.29, C = 6.18–22.84) were similar to Vivitrol® (F = 16.83, C = 6.83–23.09). These results indicate that the optimized formulation can reach an effective therapeutic concentration for treating opioid and alcohol dependence.

We also recommend Trading Suppliers and Manufacturers of Ethyl heptanoate (cas 106-30-9). Pls Click Website Link as below: cas 106-30-9 suppliers

Prev:Phase equilibrium of (water + formic or acetic acid + Ethyl heptanoate (cas 106-30-9)) ternary liquid systems at different temperatures
Next:Biotransformation of testosterone and testosterone heptanoate by four filamentous fungi)